Results 71 to 80 of about 24,887 (213)
PM&R, EarlyView.Abstract Background and Objective Previous work from this dataset found 45% prescribing frequency of any medications (35.1%, 33.5%, and 56.8% at institutions 1, 2, and 3 respectively), without significant difference between in‐person and telemedicine.
Matthew Chen +7 more
wiley +1 more source
Acta Cirúrgica Brasileira, 2021 Purpose To explore the role and molecular mechanisms of neuroprotective effects of octreotide in alcohol-induced neuropathic pain. Methods Male Wistar rats were employed and were administered a chronic ethanol diet containing 5% v/v alcohol for 28 days.
Rongqiang Jiang, Hongxia Wei
doaj +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos +4 more
wiley +1 more source
Small Bowel Lesions and Bleeding Risk in Hemodialysis Patients: A Narrative Review
Hemodialysis International, EarlyView.ABSTRACT Background Gastrointestinal bleeding is very common among hemodialysis patients. This high bleeding risk is caused by uremic platelet dysfunction, vascular fragility, intradialytic hemodynamic instability, and widespread antithrombotic therapy.
Andreas Smyrlis +3 more
wiley +1 more source
Journal of Evidence-Based Medicine, EarlyView.ABSTRACT Older patients receiving end‐of‐life palliative care often present with multiple geriatric syndromes, frailty, and comorbid symptom burden, resulting in a high risk of medication‐related harm. This guideline focuses on pharmacological management of distressing symptoms in older patients receiving end‐of‐life or hospice‐oriented palliative care,
Daiping Li +7 more
wiley +1 more source
Kaplan-Meier survival analyses and octreotide use. [PDF]
, 2013 (A) PFS median estimates for AJCC stage IV patients treated or not with octreotide were 91.2 and 50.0 months respectively; N = 40 (p = 0.004). (B) OS median estimates for AJCC stage IV patients treated or not with octreotide were 112.3 and 80.0 months ...
Stefano Serra (404838) +6 more
core +1 more source
Obesity Reviews, EarlyView.ABSTRACT Introduction Many survivors of childhood brain tumors face long‐term adverse health outcomes like obesity. Uncertainties surround the effect of interventions to manage obesity‐related outcomes in survivors of childhood brain tumors. The goal of this updated systematic review and meta‐analysis was to provide the best estimate of the treatment ...
David Hart +11 more
wiley +1 more source
Octreotide for treatment of postoperative chylothorax [PDF]
, 2001 Two infants who developed chylothorax after surgery for congenital heart disease were treated successfully with subcutaneous octreotide. Apart from reducing chyle output, octreotide decreased the triglyceride content of the pleural fluid ...
Yip, MM, Cheung, YF, Leung, MP
core +1 more source
Neonatal Network, 2006 A CHYLOTHORAX IS CHARACTERIZED BY AN ACCUMULATION OF pleural fluid having a turbid or milky white appearance due to a high lipid and triglyceride content. This continuously draining fluid, called chyle, contains lymphocytes, proteins, and immunoglobulins.
Gregory V, Stajich, Laurel, Ashworth
europepmc +4 more sources